Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Spectrum Pharmaceuticals, Inc.
The investigation focuses on whether the company and its officers violated securities laws by issuing misleading information to investors.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
On October 23, 2015, Spectrum announced that it has received a Complete Response Letter from the FDA in response to its New Drug Application (NDA) seeking clearance for Evomela, indicating that the FDA cannot approve the application in its present form.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at email@example.com.